Selective internal radiation therapy (SIRT) or sorafenib in patients with locally advanced HCC: SARAH and SIRveNIB trials
The recent SARAH and SIRveNIB trials looked to clarify the impact of SIRT versus sorafenib in patients with locally advanced HCC. What did they show? What are the implications for practice? And what other recent publications can help to shed light on this treatment question? The proceeding e-learning course will take you through our experts’ views on the results from these important studies.
Understanding the changing treatment landscape in hepatocellular carcinoma and optimising therapy for the individual patient
This e-learning course discusses the changing treatment landscape in hepatocellular carcinoma (HCC) and how therapy can be optimised for the individual patient. Key clinical questions will be addressed, including;
- When and how to transition from loco-regional to systemic therapy?
- What is the role of novel systemic therapies and immunotherapy?
- What is the impact of treatment sequencing?
During the e-learning, Experts will present different patient case studies to enhance your understanding of this area.